Symptom-driven care is falling out of favor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.
From hormone-replacement therapies to super-effective breast-cancer drugs to the so-called female Viagra, innovation within the women’s health category has accelerated in recent months.
Today’s cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment
While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen
outlines the potential threats and solutions
Therapeutic Focus Autoimmune Revised.pdf The great biosimilar debate is overshadowing brisk innovation in the autoimmune disease category. The pipeline houses promising biologics for lupus and celiac disease, and competition for Novartis’s recently approved IL-17A inhibitor for psoriasis, Cosentyx, is waiting on deck. The prevalence of autoimmune disease, in which systemic inflammation assaults the body, is…
Is this finally the year that anti-obesity drugs make the leap from niche curio to mainstream therapy? Frank Celia reports on the changing practitioner mind-set that could shift odds in favor of several new weight-loss options
The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge.
The cardiovascular space has long ranked among the pharma industry’s most vibrant. Even by that standard, however, 2015 is shaping up as a blockbuster year, and PCSK9 inhibitors have a lot to do with projections. Estimates for their success could prove even better if they are shown to reduce cardiovascular event risk, as well. Joe Dysart explains
New therapies are shaking up MS and insomnia, while the slow pace of progress in Alzheimer’s
continues to frustrate patients and physicians alike. Welcome to neurology, where, Joe Dysart
reports, treatment breakthroughs in certain areas are counteracted by setbacks in others
The anti-vaccination movement continues to make noise, but the Ebola scare has highlighted the role vaccines play in controlling diseases—and saving lives. Joe Dysart looks at the implications of the quest for an anti-Ebola vaccine, as well as the corporate shakeup in the vaccine sector.
